Friedreich's ataxia: the European consortium

More articles from this author

• Induced pluripotent stem cells-derived neurons from patients with Friedreich ataxia exhibit differential sensitivity to resveratrol and nicotinamide
• Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia
• Reata Announces Positive Topline Results from the MOXIe Registrational Trial of Omaveloxolone in Patients with Friedreich’s Ataxia
• Primary Cultures of Pure Embryonic Dorsal Root Ganglia Sensory Neurons as a New Cellular Model for Friedreich's Ataxia
• Changes detected in swallowing function in Friedreich ataxia over 12 months
• SINEUP non-coding RNAs rescue defective frataxin expression and activity in a cellular model of Friedreich's Ataxia
• Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich's Ataxia
• Health-related quality of life and depressive symptoms in Friedreich ataxia
• Unique roles of iron and zinc binding to the yeast Fe-S cluster scaffold assembly protein "Isu1"
• Mechanism of activation of the human cysteine desulfurase complex by frataxin